Vascular Access Devices Market Eyes US$ 9.9 Billion by 2032

Introduction

The Global Vascular Access Devices Market is projected to reach approximately US$ 9.9 billion by 2032, up from US$ 5.3 billion in 2022, growing at a compound annual growth rate (CAGR) of 6.6% from 2023 to 2032. This expansion is fueled by an increasing demand for medical treatments requiring vascular access, such as hemodialysis, driven by the rising prevalence of chronic kidney diseases (CKD). As more patients require dialysis, the demand for durable and reliable vascular access devices like arteriovenous (AV) fistulas and grafts intensifies due to their long-term viability and lower complication rates compared to catheters.

Technological advancements are significantly shaping the market by reducing common complications such as infections and thrombosis. Innovations include the development of antimicrobial and antithrombogenic catheters, aiming to improve patient outcomes by maintaining the patency of access sites and reducing infection rates. Such technologies are central to the evolution of vascular access solutions, enhancing patient safety and treatment efficacy.

Patient education and training also play a crucial role in the sector’s growth. Programs that teach self-cannulation techniques, especially for hemodialysis patients, help reduce needle fear and improve the dialysis experience. Educated patients can manage their vascular access better, leading to fewer complications and greater autonomy, which in turn supports market growth.

Updated clinical practice guidelines also contribute to the sector’s development by standardizing the selection and management of vascular access devices across healthcare settings. These guidelines are based on the latest research and technological advances, ensuring optimized patient care and support for continuous market growth.

Recent developments include Becton, Dickinson and Company’s acquisition of Edwards Lifesciences’ Critical Care product group in September 2024 for $4.2 billion. This move aims to expand BD’s portfolio in smart connected care solutions, including AI-enabled clinical decision tools, which are expected to boost revenue growth and margin expansion. In another strategic move, B. Braun Melsungen AG collaborated with Infraredx in March 2023 to accelerate the FDA investigational device exemption (IDE) clinical trial for the B. Braun SeQuent Please ReX, a drug-coated PTCA balloon catheter for treating coronary in-stent restenosis, addressing a significant unmet clinical need.

Key Takeaways

• In 2022, the global market value for Vascular Access Devices stood at US$ 5.3 billion.
• The market is predicted to expand at a 6.6% CAGR, reaching US$ 9.9 billion by 2032.
• Central vascular access devices led the market in 2022, with a 41.5% revenue share.
• Vascular access devices used for drug administration held a 37% revenue share in 2022.
• The global elderly population is expected to increase to 16% by 2050 and 24% by 2100.
• Approximately 771 million people worldwide, or 10% of the population, were over 65 in 2022.
• GLOBOCAN 2020 projects 19.3 million new global cancer cases.
• Cancer cases in India could reach 2.08 million by 2040, up 57.5% from 2020.
• The U.S. recorded 602,347 cancer-related deaths in 2020.
• As per the IDF Diabetes Atlas 2021, 537 million adults had diabetes globally in 2021.
• Diabetes prevalence worldwide is expected to exceed 12% by 2045.
• Hospitals and clinics are likely to lead the Vascular Access Devices market with a 45% revenue share.
• Outpatient clinics saw a 96.5% drop in clinical volume during the COVID-19 pandemic.
• Ambulatory surgical centers are poised for significant growth due to increasing chronic disease cases.

Vascular Access Devices Statistics

• Over 400 million Peripheral Intravenous Catheters (PIVCs) and more than 4 million Central Vascular Access Devices (CVADs) are sold annually in the U.S.
• Up to 90% of hospitalized patients are administered a PIVC during their stay.
• Half of the PIVCs are replaced prematurely due to complications.
• Each month, up to 63% of Emergency Department (ED) PIV insertions result in blood exposure.
• 25% of central lines in pediatric patients are removed before completing the intended therapy.
• Occlusions affect up to 36% of long-term central venous catheters.
• Up to 1 in 4 patients who develop a Central Line-Associated Bloodstream Infection (CLABSI) may die.
• About 28% of CLABSIs in acute care are caused by antimicrobial-resistant pathogens.
• An average of 82 patients contract a CLABSI daily, with 72% occurring more than 5 days after line insertion.
• The cost of CLABSIs to the U.S. healthcare system is approximately $1.9 billion annually, averaging $45,814 per infection.
• A 200-bed hospital spends over $980,000 annually due to unnecessary PIV restarts.
• Hospital-Onset Bacteremia (HOBs), unrelated to central lines, costs about $23,998 per infection.
• A systematic review found 33% to 45% of needleless connectors contaminated, with only a 10% compliance in decontamination practices.

Emerging Trends

• Advancements in Materials and Designs: The vascular access devices sector is witnessing a transformation with the adoption of advanced materials aimed at enhancing patient safety and device longevity. Innovations include the use of biocompatible materials that closely resemble human tissue, which are being employed in devices such as arteriovenous (AV) fistulas and grafts. These materials not only reduce the risk of infection but also improve the durability of the devices, reflecting a significant step forward in medical device technology.
• Wireless Power Technology: A notable trend in the sector is the shift towards wirelessly powered implantable vascular access devices. These devices eliminate the need for internal batteries, thereby reducing the frequency of surgical interventions required to replace them. Researchers are focused on developing devices that can monitor and treat conditions through wireless power, a breakthrough that promises to enhance patient comfort and safety by minimizing surgical risks.
• Minimally Invasive Techniques: There is a growing emphasis on minimally invasive techniques in the vascular access devices market. New technologies are emerging that facilitate easier and less invasive insertion and maintenance of these devices. This trend is driven by the goal to reduce patient recovery times and lower the incidence of complications associated with more invasive procedures, ultimately improving overall patient outcomes.
• Integration with Digital Health Systems: Integration with digital health systems is becoming increasingly prevalent among vascular access devices. This trend is geared towards improving the synchronization of device data with digital health records and monitoring systems. Such integration enhances the capabilities for real-time tracking of patient health outcomes, offering a more dynamic and responsive approach to patient care management.
• Personalized Vascular Access Solutions: The industry is increasingly focusing on the development of personalized vascular access solutions. Customized to each patient’s specific anatomical and health requirements, these tailored devices are designed to enhance the effectiveness and safety of treatments. This patient-centric approach in device development highlights a significant shift towards more personalized and precise medical care.

Use Cases

• Hemodialysis Access: Vascular access devices are indispensable for patients undergoing hemodialysis. An arteriovenous (AV) fistula or graft creates a durable, high-flow circuit, essential for effective blood filtration. This reliable access supports regular and efficient removal of waste products from the blood, which is crucial for patients with renal failure. By providing a stable and long-lasting vascular entry, these devices significantly improve the quality of hemodialysis sessions and patient comfort.
• Chronic Disease Management: For patients managing chronic illnesses, vascular access devices such as Peripherally Inserted Central Catheters (PICCs) and implantable ports are vital. These devices facilitate long-term administration of treatments like chemotherapy and antibiotics. By minimizing the frequency of needle sticks, they enhance patient comfort and reduce the risk of complications, making them a preferred choice for sustained therapy.
• Emergency Medicine: In critical care scenarios, immediate access to the vascular system can be life-saving. Central venous catheters are designed for such emergencies, allowing swift administration of drugs and fluids. Their use is crucial in acute settings where time and rapid response are key factors. These devices ensure that medical professionals can provide prompt and effective treatment during emergency interventions.
• Pediatric Care: Addressing the unique needs of young patients, specialized vascular access devices are tailored for pediatric care. These devices are smaller in gauge and shorter in length, suited to the delicate veins of children. Their design prioritizes safety and appropriateness, ensuring that medical treatments are administered with minimal discomfort and risk to young patients, thereby improving the overall pediatric care experience.
• Advanced Diagnostics and Treatment: The integration of smart technology in vascular access devices has revolutionized diagnostics and treatment. Power injectable PICCs, for instance, enable high-speed injection of contrast media, which is critical for advanced imaging diagnostics. This capability supports a range of sophisticated medical procedures and diagnostic tests, making these devices a cornerstone in modern medical practice, enhancing both efficiency and safety in patient care.

Conclusion

In conclusion, the Vascular Access Devices market is poised for significant growth, driven by increasing demand for chronic disease treatments and hemodialysis. Technological innovations, such as antimicrobial and antithrombogenic catheters, are crucial in enhancing patient outcomes by reducing infections and maintaining the effectiveness of access sites. Education programs in self-cannulation and updated clinical guidelines are also pivotal, promoting better management and reducing complications. Recent acquisitions and collaborations, like Becton, Dickinson and Company’s strategic purchase, indicate robust industry dynamics and a focus on expanding smart healthcare solutions. These elements collectively forecast a promising future for the market, ensuring ongoing improvements in patient care and safety.

Discuss your needs with our analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF